Therapeutic Value of Estrogen Receptor α in Hepatocellular Carcinoma Based on Molecular Mechanisms
Open Access
- 10 August 2021
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 10 (1), 140-146
- https://doi.org/10.14218/jcth.2021.00224
Abstract
The incidence of hepatocellular carcinoma (HCC) is significantly lower in women than men, implying that estrogen receptors (ERs) may play an important role in this sex dimorphism. Recently, considerable progress has been made in expanding our understanding of the mechanisms of ERs in HCC. As one of the most important ERs, ERα functions as a tumor suppressor in the progression of HCC through various pathways, such as STAT3 signaling pathways, lipid metabolism-related signaling pathways, and non-coding RNAs. However, the function of ERα was reduced with the changes of some molecules in the liver, which may develop further into HCC and make it difficult to achieve an effective hormone treatment effect. Intriguingly, there are signs that individualized hormone therapy according to the activity of ERα will overcome this challenge. Based on these observations, it is particularly imperative to reassess and extend the function of ERα. In this review, we mainly elucidated molecular mechanisms associated with ERα in HCC and investigated the individualized hormone therapy based on these mechanisms, with the aim of providing new insights for HCC treatment.Keywords
This publication has 67 references indexed in Scilit:
- Tamoxifen inhibits migration of estrogen receptor-negative hepatocellular carcinoma cells by blocking the swelling-activated chloride currentJournal of Cellular Physiology, 2013
- Foxa1 and Foxa2 Are Essential for Sexual Dimorphism in Liver CancerCell, 2012
- Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob miceThe FASEB Journal, 2011
- Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III studyBritish Journal of Cancer, 2007
- Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma CellsCancer Research, 2007
- The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinomaJournal of Hepatology, 2004
- Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related riskJournal of Hepatology, 2003
- High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trialJournal of Hepatology, 2002
- Controlled trial of tamoxifen in patients with advanced hepatocellular carcinomaJournal of Hepatology, 1994
- Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifenJournal of Hepatology, 1990